Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 1 of 6 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
|
|
- Roderick Wilkins
- 5 years ago
- Views:
Transcription
1 Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 1 of 6 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ENDO PHARMACEUTICALS INC., Plaintiff, v. Civil Action (RBW UNITED STATES FOOD AND DRUG ADMINISTRATION, et al., Defendants. DEFENDANTS RESPONSE TO THE COURT S NOVEMBER 30, 2012 ORDER On November 30, 2012, Endo Pharmaceuticals Inc., ( Endo filed a complaint and motion for preliminary injunction against the U.S. Food and Drug Administration, Commissioner Hamburg, and the U.S. Department of Health and Human Services Secretary Sebelius (hereinafter, FDA. 1 The case concerns the drug product oxymorphone HCl, extended-release tablets, marketed by Endo since 2006 under the brand-name Opana ER. On the same day the case was filed, and before setting a briefing schedule or hearing date, this Court ordered FDA to respond to two questions. This filing is FDA s response to that Court order. I. Does the Court have jurisdiction to entertain the plaintiff s motion prior to the date on which FDA is required to act under 21 U.S.C. 355(j(6 and 21 C.F.R (a? The Court has jurisdiction to entertain Endo s motion for preliminary injunction to the extent it claims that FDA has unreasonably delayed rendering a decision whether, under 21 1 FDA notes that Endo failed to satisfy its duty to confer under LCvR 7(m. Counsel first notified FDA of this matter Friday afternoon at 3:56 pm and did not attempt to confer with agency counsel prior to filing its complaint or motion for preliminary injunction.
2 Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 2 of 6 U.S.C. 355(j(6 and 21 C.F.R , the original Opana ER product was removed from the market for safety or effectiveness reasons. However, that claim fails under Federal Rule of Civil Procedure 12(b(6 because FDA has no duty to act before December 31, 2012, despite Endo s arguments to the contrary. Endo filed a citizen petition with FDA dated August 10, 2012, 2 that asks FDA to take several actions including, as relevant to the Court s jurisdictional question, making a determination, under 21 C.F.R , that the original Opana ER was removed from the market for safety reasons. 3 A recent amendment to the Federal Food, Drug, and Cosmetic Act gives FDA 270 days from the date of submission to respond substantively to a citizen petition requesting such a determination. See 21 U.S.C. 355(w. Mention of this statutory deadline is conspicuously absent from Endo s filings. Yet, despite a statutory deadline for FDA s response that is many months away, Endo nonetheless argues that FDA has unreasonably delayed responding to its citizen petition. This claim is subject to dismissal under Fed. R. Civ. P. 12(b(6 because Endo has not shown that FDA has a duty to act prior to May 10, days after Endo s citizen petition was submitted to FDA. Endo s unreasonable delay claim fails not only because of the statutory 270-day deadline, but also because it is far from unreasonable for FDA to take sufficient time to make the requested determination. Endo does not suggest that the withdrawn product is less safe than the 2 Endo filed a second citizen petition with FDA, dated August 31, 2012, but that petition does not involve application of 21 U.S.C. 355(j(6 or 21 C.F.R and is therefore not relevant to the Court s questions. 3 On August 30, 2011, FDA determined, in response to a citizen petition from a generic manufacturer, that two strengths of the original Opana ER (7.5 mg and 15 mg were not withdrawn from the market for reasons of safety or effectiveness. See 76 Fed. Reg (Aug. 30, This determination was made before Endo s new formulation of Opana ER was approved in December Endo s citizen petition requesting a determination is not limited to any particular strengths of the original Opana ER. 2
3 Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 3 of 6 new formulation for the intended user. Instead, Endo s request that FDA make a section determination raises inter alia complex and novel legal issues concerning: (1 whether a product that was previously considered safe and effective must now be found unsafe or ineffective because a manufacturer claims that a safer or more effective product has been introduced to the market; and (2 whether the potential for misuse of a drug product by a population other than the intended user constitutes a safety concern under 21 U.S.C. 355(j(6 and 21 C.F.R that requires FDA to conclude the drug was withdrawn for safety or effectiveness reasons. In addition, if FDA were to conclude that Endo s original Opana ER product was removed from the market for safety or effectiveness reasons, FDA would then have to decide what process is required to withdraw approval of previously approved products. To determine these issues, FDA must also resolve the complex scientific question whether Endo s new formulation for Opana ER is safer or more effective than Opana s old formulation, particularly in light of the fact that FDA has approved no labeling for Opana s new formulation that suggests a reduced potential for abuse exists. Compare new Opana ER label (available at with old Opana ER label (available at (the only relevant difference between the labels is the description of the tablets shape (round vs. octagonal; the abuse potential sections of the labels are identical. Because FDA needs adequate time to consider and analyze the relevant legal and factual issues, including analysis of data relating to the alleged safety advantage of the new formulation (which Endo submitted just weeks ago, on November 13, the agency has not yet determined whether all strengths of the original Opana ER were removed from the market for safety reasons, and is not likely to reach such a determination by December 31, as Endo desires. In these circumstances, any alleged 3
4 Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 4 of 6 delay on FDA s part is eminently reasonable. Endo s urgent desire to block previously approved generics from competing in the marketplace, which competition Endo believes will begin on January 1, 2013, does not translate into a mandatory requirement that FDA reorder its priorities and respond to Endo s citizen petition by December 31, Apart from the 270-day deadline that governs FDA s response to Endo s citizen petition in this case, neither 21 U.S.C. 355(j(6 nor 21 C.F.R (a establish a deadline by which FDA must determine whether Endo s product was removed from the market for safety reasons. Endo reads into both the statutory provision and the regulation a requirement that FDA act by December 31, There is no statutory or regulatory support for Endo s claim. Indeed, the December 31 date is a function of Endo s own creation necessitated by its own commercial decision-making. In settlement of patent litigation, Endo granted a license to a generic manufacturer, Impax Laboratories Inc. ( Impax, that permits Impax to begin marketing a generic version of the original Opana ER on January 1, But a different generic version of two strengths of the original Opana ER, marketed by Actavis South Atlantic ( Actavis, was introduced in July 2011, see and it is FDA s understanding that those strengths continue to be marketed today. Endo s self-inflicted December 31 deadline is a thinly-veiled attempt to maintain its market-share and block generic competition from Impax. 4 4 Notably, Endo has patent protections on its new formulation of Opana ER that have the potential to prevent generic competition until approximately See _No=007&table1=OB_Rx (Orange Book entry showing the drug substance patent that is listed only for the new formulation of Opana ER, patent number 7,851,482, expires on July 10,
5 Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 5 of 6 II. Would the FDA authorize the marketing of a generic drug that has already been approved prior to reaching a determination under 21 U.S.C. 355(j(6 and 21 C.F.R (a whether the plaintiff s product was withdrawn from the market for safety reasons? FDA does not authorize the marketing of generic drugs separately from approving those products. Once FDA issues a final approval under 21 U.S.C. 355(j, which is a finding by FDA that the generic product meets all the requirements for generic approval and therefore the product is safe and effective, the manufacturer can immediately begin marketing the approved product. As Endo noted in its Memorandum Of Points And Authorities In Support Of Plaintiff s Motion For Preliminary Injunction ( PI Mem., two abbreviated new drug applications ( ANDAs for generic versions of the original Opana ER were approved in December 2010, before Endo removed its product from the market. PI Mem. at 2. Those ANDAs belong to Impax and Actavis. As noted above, Actavis began marketing two strengths of its generic product on July 15, See In FDA s view, Impax was also permitted to begin marketing its product immediately upon approval. Impax, however, is apparently blocked by a patent license agreement with Endo from marketing until January 1, See PI Mem. at 13, n.20. FDA was not, and is not, a party to that licensing agreement. FDA assures the Court that it will not approve any other ANDAs that reference the original Opana ER without first determining whether the product was removed from the market for reasons of safety or effectiveness, in accordance with 21 U.S.C. 355(j(6 and 21 C.F.R (a. However, products that have already been approved (including Impax s product, Actavis product, and Endo s own original product may continue to be lawfully marketed unless and until FDA determines that Endo s original Opana ER was in fact removed from the market for reasons of safety and effectiveness. Indeed, Endo itself could resume marketing its original 5
6 Case 1:12-cv RBW Document 9 Filed 12/03/12 Page 6 of 6 Opana ER tomorrow should it choose, because FDA s finding that Endo s product is safe and effective remains, as of this date, unchanged. The fact that Endo s own labeling for the new Opana ER product is largely identical to the original Opana ER label except for the description of the tablets shape, as explained above, confirms that Endo s true interest in expedited FDA consideration stems from business concerns rather than protection of the public health. * * * Because Endo has no likelihood of success on its ill-conceived, eleventh-hour motion for exigent relief, the Court should deny it on that basis alone. Alternatively, FDA requests that the Court set a reasonable, non-expedited briefing schedule on Endo s motion for preliminary injunction together with the government s anticipated motion to dismiss Endo s unreasonable delay claim. Respectfully submitted, OF COUNSEL: WILLIAM B. SCHULTZ Acting General Counsel ELIZABETH H. DICKINSON Associate General Counsel, Food and Drug Division STUART F. DELERY Principal Deputy Assistant Attorney General MAAME EWUSI-MENSAH FRIMPONG Deputy Assistant Attorney General MICHAEL S. BLUME Director ERIC M. BLUMBERG /s/ Deputy Chief Counsel, Litigation ANDREW E. CLARK Assistant Director SHOSHANA HUTCHINSON Consumer Protection Branch Associate Chief Counsel Civil Division U.S. Department of Health & Human Services Department of Justice Office of the General Counsel P.O. Box New Hampshire Avenue Washington, DC Silver Spring, MD andrew.clark@usdoj.gov December 3,
Case 5:13-cv SMH-MLH Document 1 Filed 06/20/13 Page 1 of 11 PageID #: 1
Case 5:13-cv-01983-SMH-MLH Document 1 Filed 06/20/13 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA SHREVEPORT DIVISION UNITED STATES OF AMERICA v. Plaintiff,
More informationCase 1:17-cv EGS Document 18 Filed 09/15/17 Page 1 of 6 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:17-cv-01085-EGS Document 18 Filed 09/15/17 Page 1 of 6 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA CENTER FOR SCIENCE IN THE PUBLIC INTEREST and NATIONAL CONSUMERS LEAGUE, v. Plaintiffs,
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA. ) ) ) ) ) ) ) ) ) ) ) Plaintiffs, ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Defendants.
Case 1:16-cv-01350 Document 1 Filed 06/28/16 Page 1 of 19 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA LANNETT COMPANY, INC., 13200 Townsend Road, Philadelphia, PA 19154 and LANNETT
More informationHOGAN & HARTSON APR -9 P4 :18 BY HAND DELIVERY
HOGAN & HARTSON 2741 10 APR -9 P4 :18 Hogan & Hartson up Columbia Square 555 Thirteenth Street, NW Washington, DC 20004 +1.202.637.5600 Tel +1.202.637.5910 Fax www.hhlaw.com Philip Katz Partner 202.637.5632
More informationCase4:12-cv PJH Document82-1 Filed02/20/14 Page1 of 11
Case:-cv-0-PJH Document- Filed0// Page of 0 GEORGE A. KIMBRELL (Pro Hac Vice PAIGE M. TOMASELLI State Bar No. RACHEL A. ZUBATY State Bar No. 0 Center for Food Safety 0 Sacramento St., nd Floor San Francisco,
More informationGuidance for Industry
Guidance for Industry Citizen Petitions and Petitions for Stay ofaction Subject to Section 505(q) ofthe Federal Food, Drug, and Cosmetic Act DRAFT GUIDANCE This guidance document is being distributed for
More informationCase 1:17-cv Document 1 Filed 08/04/17 Page 1 of 15
Case 1:17-cv-01577 Document 1 Filed 08/04/17 Page 1 of 15 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA UNITED THERAPEUTICS CORPORATION, 1040 Spring Street Silver Spring, MD 20910 v.
More informationUNITED STATES DISTRICT COURT DISTRICT OF NEV ADA. consented to the entry of this Consent Decree of Permanent Injunction (the "Decree"), without
USA v. Bio Health Solutions, LLC Doc. 3 1 UNITED STATES DISTRICT COURT DISTRICT OF NEV ADA 3 4 6 7 10 UNITED ST A TES OF AMERICA, Plaintiff, v. BIO HEAL TH SOLUTIONS, LLC and MARK GARRISON, Defendants.
More informationCase 1:16-cv UNA Document 1 Filed 09/30/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00886-UNA Document 1 Filed 09/30/16 Page 1 of 11 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC. and UCB PHARMA GMBH, v. Plaintiffs, AUROBINDO PHARMA
More informationCase 1:14-cv BAH Document 68-1 Filed 01/26/15 Page 1 of 5 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:14-cv-01923-BAH Document 68-1 Filed 01/26/15 Page 1 of 5 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA RANBAXY LABORATORIES, LTD. and RANBAXY, INC., v. Plaintiffs, SYLVIA MATHEWS BURWELL,
More informationCase 1:16-cv UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00015-UNA Document 1 Filed 01/15/16 Page 1 of 13 PageID #: 1 PROSTRAKAN, INC. and STRAKAN INTERNATIONAL S.á r.l., IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE v. Plaintiffs,
More informationCase 1:10-cv UNA Document 1 Filed 10/05/10 Page 1 of 20
Case 1:10-cv-00852-UNA Document 1 Filed 10/05/10 Page 1 of 20 Case 1:10-cv-00852-UNA Document 1 Filed 10/05/10 Page 2 of 20 4. Plaintiff Allergan Sales, LLC is a corporation organized and existing under
More informationProposal to Refuse to Approve a New Drug Application for Oxycodone Hydrochloride
This document is scheduled to be published in the Federal Register on 02/13/2018 and available online at https://federalregister.gov/d/2018-02903, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationA. ANDAs and Eligibility for 180-day Exclusivity
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 SENT VIA ELECTRONIC MAIL Dear Celecoxib ANDA Applicant: This letter addresses the legal and regulatory scheme governing
More informationCase 1:16-cv UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) ) ) ) ) ) ) ) )
Case 1:16-cv-00237-UNA Document 1 Filed 04/07/16 Page 1 of 17 PageID #: 1 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FRESENIUS KABI USA, LLC, Plaintiff, v. MAIA PHARMACEUTICALS, INC., Defendant.
More informationCase 1:07-cv RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:07-cv-00579-RMU Document 81 Filed 06/27/2007 Page 1 of 14 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA MYLAN LABORATORIES, INC., et al., Plaintiffs, v. Civil Action No. 07-0579 (RMU
More informationIN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION COMPLAINT FOR PATENT INFRINGEMENT
IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION GALDERMA LABORATORIES, L.P., GALDERMA S.A., and GALDERMA RESEARCH & DEVELOPMENT, S.N.C., v. Plaintiffs, ACTAVIS MID
More informationCase: 1:16-cv Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION
Case: 1:16-cv-02988 Document #: 1 Filed: 03/09/16 Page 1 of 13 PageID #:1 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION TORRENT PHARMACEUTICALS LIMITED, and TORRENT PHARMA
More informationPHARMACEUTICAL LAW GROUP PC
in L PHARMACEUTICAL LAW GROUP PC AT THE INTERSECTION OF FDA REGULATION AND INTELLECTUAL PROPERTY 900 SEVENTH STREET, NW - SUITE 650 - WASHINGTON, DC 20001-3886 T 202 589 1780 F 202 318 2198 WWW.PHARMALAWGRP.COM
More informationCase 1:16-cv UNA Document 1 Filed 10/13/16 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00942-UNA Document 1 Filed 10/13/16 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ASTELLAS PHARMA INC., ASTELLAS IRELAND CO., LTD., and ASTELLAS
More informationCase 1:17-cv UNA Document 1 Filed 12/22/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-01844-UNA Document 1 Filed 12/22/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AMGEN INC., v. Plaintiff, TORRENT PHARMACEUTICALS LTD. and TORRENT
More informationLitigation Webinar Series. Hatch-Waxman 101. Chad Shear Principal, San Diego
Litigation Webinar Series Hatch-Waxman 101 Chad Shear Principal, San Diego 1 Overview Hatch-Waxman Series Housekeeping CLE Contact: Jane Lundberg lundberg@fr.com Questions January 25, 2018 INSIGHTS Litigation
More informationCase 1:17-cv Document 1 Filed 07/11/17 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR DISTRICT OF COLUMBIA
Case 1:17-cv-01358 Document 1 Filed 07/11/17 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR DISTRICT OF COLUMBIA STORY OF STUFF PROJECT, 1442 A Walnut St. #272, Berkeley, CA 94709; and COURAGE CAMPAIGN
More informationCase 1:15-cv LPS Document 118 Filed 05/10/16 Page 1 of 11 PageID #: 2856 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:15-cv-00164-LPS Document 118 Filed 05/10/16 Page 1 of 11 PageID #: 2856 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE COSMO TECHNOLOGIES LIMITED, VALEANT PHARMACEUTICALS INTERNATIONAL,
More informationCase 1:18-cv LPS Document 1 Filed 01/12/18 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00092-LPS Document 1 Filed 01/12/18 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE H. LUNDBECK A/S, TAKEDA PHARMACEUTICAL COMPANY LTD., TAKEDA PHARMACEUTICALS
More informationTeva Pharmaceuticals USA Attention: Scott Tomsky Vice President, U.S. Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 091028 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott Tomsky Vice President, U.S. Generics Regulatory Affairs
More informationCase 1:07-cv RMU Document 71-2 Filed 05/08/2007 Page 1 of 6. ANDA , Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg.
Case 1:07-cv-00579-RMU Document 71-2 Filed 05/08/2007 Page 1 of 6 DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 76-719, Amlodipine Besylate Tablets, 2.5 mg, 5 mg, and 10 mg. SENT BY FACSIMILE AND U.S. MAIL
More informationCase 1:09-cv UNA Document 1 Filed 07/13/2009 Page 1 of 17
Case 1:09-cv-00511-UNA Document 1 Filed 07/13/2009 Page 1 of 17 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALLERGAN, INC., ALLERGAN USA, INC., ALLERGAN SALES, LLC, ENDO PHARMACEUTICALS
More informationCase 1:10-cv MGC Document 11-1 Filed 11/18/10 Page 1 of 55 EXHIBIT A
Case 1:10-cv-08386-MGC Document 11-1 Filed 11/18/10 Page 1 of 55 EXHIBIT A Case 1:10-cv-08386-MGC Document 11-1 Filed 11/18/10 Page 2 of 55 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA PUBLIC EMPLOYEES FOR ) ENVIRONMENTAL RESPONSIBILITY ) 962 Wayne Ave., Suite 610 ) Silver Spring, MD 20910 ) Civil Action 18-cv-45 ) Plaintiff,
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF MINNESOTA Civil No
CASE 0:15-cv-02168 Document 1 Filed 04/27/15 Page 1 of 10 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MINNESOTA Civil No. 15-2168 UNITED STATES OF AMERICA, ) ) Plaintiff ) ) v. ) ) COMPLAINT FOR MEDTRONIC
More informationUnited States District Court EASTERN DISTRICT OF TEXAS TYLER DIVISION
Case 6:11-cv-00441-MHS Document 304 Filed 01/13/14 Page 1 of 5 PageID #: 8335 United States District Court EASTERN DISTRICT OF TEXAS TYLER DIVISION ALLERGAN, INC. v. Cause No. 6:11-cv-441 Consolidated
More informationFor reprint orders, please contact Endo Pharmaceuticals Inc. v. Actavis, Inc. Alexandra Sklan*,1 & Takeshi S Komatani 2
For reprint orders, please contact reprints@future-science.com International roundup of recently filed cases and noteworthy rulings Alexandra Sklan*,1 & Takeshi S Komatani 2 Endo Pharmaceuticals Inc. v.
More informationIN THE UNITED STATES COURT OF APPEALS FOR THE DISTRICT OF COLUMBIA CIRCUIT
USCA Case #11-1066 Document #1420668 Filed: 02/14/2013 Page 1 of 7 IN THE UNITED STATES COURT OF APPEALS FOR THE DISTRICT OF COLUMBIA CIRCUIT NATIONAL ASSOCIATION OF REGULATORY ) UTILITY COMMISSIONERS,
More informationCase 3:12-cv PGS-LHG Document 1 Filed 06/25/12 Page 1 of 41 PageID: 1
Case 3:12-cv-03893-PGS-LHG Document 1 Filed 06/25/12 Page 1 of 41 PageID: 1 Liza M. Walsh CONNELL FOLEY LLP 85 Livingston Avenue Roseland, New Jersey 07068 (973) 535-0500 Of Counsel: Dimitrios T. Drivas
More informationo 1205 Culbreth Dr., Suite 200, Wilmington, NC Phone : Facsimile :
Osmotica Pharmaceutical 1?54,Lt. 27 P2 :05 BY HAND DELIVERY Division of Dockets Management Food and Drug Administration Department of Health and Human Services 563"0 Fishers Lane, Room 1061 Rockville,
More informationAmendments to Regulations on Citizen Petitions, Petitions for Stay of Action, and Submission of
This document is scheduled to be published in the Federal Register on 11/08/2016 and available online at https://federalregister.gov/d/2016-26912, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationCase 1:18-cv UNA Document 1 Filed 01/19/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00117-UNA Document 1 Filed 01/19/18 Page 1 of 14 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TEVA PHARMACEUTICALS INTERNATIONAL GMBH, CEPHALON, INC., and EAGLE
More informationCase 3:10-cv JAP -TJB Document 1 Filed 08/16/10 Page 1 of 13 PageID: 1
Case 3:10-cv-04205-JAP -TJB Document 1 Filed 08/16/10 Page 1 of 13 PageID: 1 John E. Flaherty Jonathan M.H. Short McCARTER & ENGLISH, LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07109
More informationCase 2:18-cv Document 1 Filed 07/10/18 Page 1 of 218 PageID: 1 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
Case 2:18-cv-11518 Document 1 Filed 07/10/18 Page 1 of 218 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING ARNSTEIN & LEHR LLP One Riverfront Plaza, Suite 1520 Newark, NJ 07102-5426 (973) 286-6700
More informationIN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION
IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION GALDERMA LABORATORIES, L.P., GALDERMA S.A., and GALDERMA RESEARCH & DEVELOPMENT, S.N.C., v. Plaintiffs, ACTAVIS LABORATORIES
More informationFormal Dispute Resolution: Appeals Above the Division Level Guidance for Industry and Review Staff
Formal Dispute Resolution: Appeals Above the Division Level Guidance for Industry and Review Staff Good Review Practice DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More information(4- I. Background. Douald O. Beers Arnold & Porter LLP 555 Twelfth Street, N.W. Washington, D.c
(4- DEPARTMENT OF HEALTH &. HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 Douald O. Beers Arnold & Porter LLP 555 Twelfth Street, N.W. Washington, D.c. 20004-1206
More informationCase 8:14-cv GJH Document 1 Filed 08/19/14 Page 1 of 22
Case 8:14-cv-02662-GJH Document 1 Filed 08/19/14 Page 1 of 22 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND Hospira, Inc. 275 N. Field Drive Lake Forest, IL 60045, v. Plaintiff, Sylvia
More informationCase 2:15-cv WHW-CLW Document 1 Filed 08/31/15 Page 1 of 145 PageID: 1
Case 2:15-cv-06541-WHW-CLW Document 1 Filed 08/31/15 Page 1 of 145 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza, Suite 1520 Newark, New Jersey 07102-5426 (973) 286-6700
More information*CLMNT_IDNO* - UAA - <<SequenceNo>>
NAMENDA DIRECT PURCHASER CLAIMS ADMINISTRATOR C/O RUST CONSULTING 6269 PO BOX 44 MINNEAPOLIS, MN 55440-0044 IMPORTANT LEGAL MATERIALS *CLMNT_IDNO* - UAA -
More informationCase 3:18-cv FLW-LHG Document 1 Filed 01/26/18 Page 1 of 25 PageID: 1
Case 3:18-cv-01097-FLW-LHG Document 1 Filed 01/26/18 Page 1 of 25 PageID: 1 Cynthia S. Betz Ravin R. Patel McCARTER & ENGLISH LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102 (973)
More informationIff/]) FEB Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC
DEPARTMENT OF HEALTH &. HUMAN SERVICES FEB 2 2 2011 Food and Drug Administration Rockville MD 20857 Gregory 1. Glover Pharmaceutical Law Group PC 900 Seventh Street, NW Suite 650 Washington, DC 20001-3886
More informationSegal McCambridge Singer & Mahoney, Ltd Market Street, Suite 2600 Philadelphia, PA (215) Fax: (215) : : : : : : : : : :
Theodore C. Flowers, Esquire tflowers@smsm.com Attorney Identification No. 82218 Segal McCambridge Singer & Mahoney, Ltd. 1818 Market Street, Suite 2600 Philadelphia, PA 19103 (215) 972-8015 Fax (215)
More informationCase 6:16-cv Document 1 Filed 03/21/16 Page 1 of 9 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS
Case 6:16-cv-01072 Document 1 Filed 03/21/16 Page 1 of 9 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS UNITED STATES OF AMERICA, ) ) Plaintiff, ) CIVIL ACTION NO. 16-1072 ) v. ) ) NATIVE
More informationIN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION
IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v. ) No. 13 C 2606 ) GOURMET EXPRESS MARKETING, ) Judge Gottschall
More informationCase 1:18-cv RJL Document 28 Filed 11/07/18 Page 1 of 6 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:18-cv-02133-RJL Document 28 Filed 11/07/18 Page 1 of 6 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ASSOCIATION FOR COMMUNITY AFFILIATED PLANS, et al., Plaintiffs, v. Civil Action
More informationCase 1:08-cv Document 1 Filed 02/04/2008 Page 1 of 7 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS
IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS FOREST LABORATORIES, INC., FOREST LABORATORIES HOLDINGS, LTD., MERZ PHARMA GMBH & CO. KGAA, and MERZ PHARMACEUTICALS GMBH, Plaintiffs,
More information2013 PA Super 215. Appellants No. 83 EDA 2012
2013 PA Super 215 IN RE: REGLAN/METOCLOPRAMIDE LITIGATION, IN THE SUPERIOR COURT OF PENNSYLVANIA APPEAL OF: MORTON GROVE PHARMACEUTICALS INC., AND WOCKHARDT USA, LLC, Appellants No. 83 EDA 2012 Appeal
More informationCase 1:12-cv SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:12-cv-00809-SLR Document 18 Filed 08/27/12 Page 1 of 17 PageID #: 71 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., WYETH LLC, WYETH PHARMACEUTICALS INC., and PF PRISM
More informationCase 1:14-cv IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959
Case 1:14-cv-00075-IMK Document 125 Filed 06/16/14 Page 1 of 21 PageID #: 1959 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA MYLAN PHARMACEUTICALS, INC., Plaintiff, WATSON
More informationCase 3:14-cv MLC-TJB Document Filed 07/24/15 Page 2 of 16 PageID: 1111 TABLE OF CONTENTS INTRODUCTION... 1 BACKGROUND...
Case 3:14-cv-02550-MLC-TJB Document 100-1 Filed 07/24/15 Page 1 of 16 PageID: 1110 Keith J. Miller Michael J. Gesualdo ROBINSON MILLER LLC One Newark Center, 19th Floor Newark, New Jersey 07102 Telephone:
More informationCase 3:15-cv MAS-LHG Document 1 Filed 04/06/15 Page 1 of 38 PageID: 1
Case 3:15-cv-02520-MAS-LHG Document 1 Filed 04/06/15 Page 1 of 38 PageID: 1 Liza M. Walsh, Esq. CONNELL FOLEY LLP 85 Livingston Avenue Roseland, New Jersey 07068-1765 (973) 535-0500 Of Counsel: William
More informationCase 3:16-cv MAS-LHG Document 1 Filed 09/16/16 Page 1 of 14 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 3:16-cv-05678-MAS-LHG Document 1 Filed 09/16/16 Page 1 of 14 PageID: 1 Liza M. Walsh Tricia B. O Reilly Katelyn O Reilly WALSH PIZZI O REILLY FALANGA LLP 1037 Raymond Boulevard, Suite 600 Newark,
More informationA. Bayer's New Drug Application for Precose
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 William A. Rakoczy, Esq. Rakoczy, Molino, Mazzochi & Siwik, LLP 6 West Hubbard St. Suite 500 Chicago, IL 60610 Dear
More informationUNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF TEXAS GALVESTON DIVISION
Case 3:15-cv-00162 Document 132 Filed in TXSD on 08/22/18 Page 1 of 6 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF TEXAS GALVESTON DIVISION STATE OF TEXAS, et al., Plaintiffs, v. U.S. ENVIRONMENTAL
More informationCase 1:11-cv LPS Document 497 Filed 05/20/14 Page 1 of 9 PageID #: IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:11-cv-00704-LPS Document 497 Filed 05/20/14 Page 1 of 9 PageID #: 17900 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE AVANIR PHARMACEUTICALS, INC., AVANIR HOLDING COMPANY, AND
More informationLupin Pharmaceutkals,Inc.
Lupin Pharmaceutkals,Inc. 1011 1 9 A 8 : 43 VIA FEDERAL EXPRESS Division of Documents Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane Room 1061 Rockville,
More informationSuitability Petition (SP)
Suitability Petitions Dr. Ken Harshman, Director Division of Generic Animal Drugs Center for Veterinary Medicine AAVPT Workshop Veterinary Drug Regulatory Life Cycle (A to Z) March 2, 2011 Suitability
More informationCase 1:10-cv JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 110-cv-00137-JCJ Document 20 Filed 04/14/10 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE MILLENNIUM PHARMACEUTICALS, INC. and SCHERING CORP., Plaintiffs, CIVIL ACTION
More informationUnited States Court of Appeals. Third Circuit
Case: 13-4096 Document: 003111694316 Page: 1 Date Filed: 07/30/2014 Case Nos. 13-3981; 13-4096 United States Court of Appeals for the Third Circuit ENDO PHARMACEUTICALS INC., v. ACTAVIS, INC., and ACTAVIS
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA COMPLAINT
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA PUBLIC EMPLOYEES FOR ENVIRONMENTAL GFRESPONSIBILITY, 962 Wayne Ave, Suite 610 CIVIL ACTION NO. COMPLAINT Silver Spring, MD 20910 Plaintiff, U.S.
More informationCase 2:15-cv MWF-MRW Document 9 Filed 03/26/15 Page 1 of 32 Page ID #:70 UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA
Case :-cv-000-mwf-mrw Document Filed 0// Page of Page ID #:0 0 JOYCE R. BRANDA Acting Assistant Attorney General Civil Division JONATHAN F. OLIN Deputy Assistant Attorney General MICHAEL S. BLUME Director,
More informationCase 1:99-cv DLC Document 101 Filed 08/05/13 Page 1 of 10
Case 199-cv-09887-DLC Document 101 Filed 08/05/13 Page 1 of 10 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------- ASTRA AKTIEBOLAG, et al., -v- Plaintiffs,
More informationCase 1:16-cv UNA Document 1 Filed 03/31/16 Page 1 of 12 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:16-cv-00207-UNA Document 1 Filed 03/31/16 Page 1 of 12 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE GALDERMA LABORATORIES, L.P.; NESTLÉ SKIN HEALTH S.A.; and TCD
More informationThe Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act
FEBRUARY 2015 The Korean Drug Approval-Patent Linkage System: A Comparison with the US Hatch-Waxman Act Authors: Ki Young Kim, Hyunsuk Jin, Samuel SungMok Lee Pursuant to the implementation of the Korea-US
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
R.J. REYNOLDS TOBACCO COMPANY et al v. UNITED STATES FOOD AND DRUG ADMINISTRATION et al Doc. 19 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA R.J. REYNOLDS TOBACCO COMPANY, 401 North Main Street
More informationRegulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products;
This document is scheduled to be published in the Federal Register on 01/07/2016 and available online at http://federalregister.gov/a/2016-00066, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationUNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN
îæïìó½ªóïíðééóßýóóöø ܱ½ ý ïëóï Ú»¼ ðíñîìñïë й ï ±º ïê й Ü êê UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN UNITED STATES OF AMERICA, ) ) Plaintiff, ) Case No. 2:14-cv-13077 ) v. ) ) S. SERRA
More informationCase 1:14-cv SLR-SRF Document 61 Filed 05/22/15 Page 1 of 20 PageID #: 634 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:14-cv-01083-SLR-SRF Document 61 Filed 05/22/15 Page 1 of 20 PageID #: 634 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE UCB, INC., UCB MANUFACTURING IRELAND LIMITED, UCB PHARMA
More informationUnited States Court of Appeals for the Federal Circuit
United States Court of Appeals for the Federal Circuit TEVA PHARMACEUTICALS USA, INC., THROUGH ITS GATE PHARMACEUTICALS DIVISION, Plaintiff-Appellant, v. EISAI CO., LTD. AND EISAI MEDICAL RESEARCH, INC.,
More informationCaraco V. Novo Nordisk: Antitrust Implications
Portfolio Media. Inc. 860 Broadway, 6th Floor New York, NY 10003 www.law360.com Phone: +1 646 783 7100 Fax: +1 646 783 7161 customerservice@law360.com Caraco V. Novo Nordisk: Antitrust Implications Law360,
More informationCase: Document: 17 Page: 1 05/13/ Eastern District of New York, Korman, J.
Case: 13-1690 Document: 17 Page: 1 05/13/2013 935254 24 UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT Thurgood Marshall U.S. Courthouse 40 Foley Square, New York, NY 10007 Telephone: 212-857-8500
More informationCase 1:18-cv IMK Document 250 Filed 08/30/18 Page 1 of 11 PageID #: 2905 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:18-cv-00226-IMK Document 250 Filed 08/30/18 Page 1 of 11 PageID #: 2905 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALLERGAN SALES, LLC, FOREST LABORATORIES HOLDINGS, LTD.,
More informationCase 1:11-cv RHS-WDS Document 5 Filed 11/10/11 Page 1 of 14 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO
Case 1:11-cv-00946-RHS-WDS Document 5 Filed 11/10/11 Page 1 of 14 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO LOS ALAMOS STUDY GROUP, v. Plaintiff, UNITED STATES DEPARTMENT OF ENERGY,
More informationCase 1:11-cv RGA Document 10 Filed 01/13/12 Page 1 of 14 PageID #: 47
Case 1:11-cv-01105-RGA Document 10 Filed 01/13/12 Page 1 of 14 PageID #: 47 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE WARNER CHILCOTT COMPANY, LLC, v. Plaintiff, ZYDUS PHARMACEUTICALS
More informationAttorneys for Defendants Watson Laboratories, Inc. and Watson Pharmaceuticals, Inc.
Case 2:10-cv-00080-FSH -PS Document 15 Filed 03/01/10 Page 1 of 14 HELLRING LINDEMAN GOLDSTEIN & SIEGAL LLP Matthew E. Moloshok, Esq. Robert S. Raymar, Esq. One Gateway Center Newark, New Jersey 07102-5386
More informationCase 1:17-cv UNA Document 1 Filed 10/20/17 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-01481-UNA Document 1 Filed 10/20/17 Page 1 of 8 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC, FOREST LABORATORIES HOLDINGS, LTD., ALLERGAN
More informationLaser Products--Conformance with IEC Ed. 3 and IEC Ed. 3.1 (Laser
This document is scheduled to be published in the Federal Register on 01/19/2018 and available online at https://federalregister.gov/d/2018-00898, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationCase 2:15-cv WHW-CLW Document 1 Filed 04/10/15 Page 1 of 81 PageID: 1
Case 2:15-cv-02571-WHW-CLW Document 1 Filed 04/10/15 Page 1 of 81 PageID: 1 Walter W. Brown U.S. Department of Justice 1100 L. St. N.W. Washington, D.C. 20005 (202) 307-0341 walter.brown2@usdoj.gov Attorneys
More informationUNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA PUBLIC EMPLOYEES FOR ) ENVIRONMENTAL RESPONSIBILITY, ) 962 Wayne Ave, Suite 610 ) Silver Spring, MD 20910 ) Civil Action No. 18-cv-1720 ) Plaintiff,
More informationPharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1
Pharmaceutical Product Improvements and Life Cycle Management Antitrust Pitfalls 1 The terms product switching, product hopping and line extension are often used to describe the strategy of protecting
More informationCase 1:15-cv RMB-JS Document 1 Filed 10/09/15 Page 1 of 14 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY
Case 1:15-cv-07415-RMB-JS Document 1 Filed 10/09/15 Page 1 of 14 PageID: 1 John E. Flaherty Ravin R. Patel McCARTER & ENGLISH LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102 (973)
More informationUNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY ) THE UNITED STATES OF AMERICA ) and THE BOARD OF TRUSTEES OF ) THE UNIVERSITY OF ILLINOIS, ) Civil Action No. ) Plaintiffs, ) COMPLAINT FOR ) PATENT
More informationAn ANDA Update. June 2004 Bulletin 04-50
June 2004 Bulletin 04-50 If you have questions or would like additional information on the material covered in this Bulletin, please contact one of the authors: Mark R. Shanks 202.414.9201 mshanks@reedsmith.com
More informationReview of Existing General Regulatory and Information Collection Requirements of the
This document is scheduled to be published in the Federal Register on 09/08/2017 and available online at https://federalregister.gov/d/2017-19047, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationCase 1:12-cv ERK-VVP Document 106 Filed 06/12/13 Page 1 of 6 PageID #: against - No. 12-CV-763 (ERK)(VVP)
Case 1:12-cv-00763-ERK-VVP Document 106 Filed 06/12/13 Page 1 of 6 PageID #: 2404 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -----------------------------------------------------------------X
More informationCase 2:09-cv DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 : :
Case 2:09-cv-01302-DMC-MF Document 17 Filed 04/20/2009 Page 1 of 28 WINSTON & STRAWN LLP The Legal Center One Riverfront Plaza, 7th Floor Newark, New Jersey 07102 (973) 848-7676 James S. Richter Attorneys
More informationCase 1:17-cv CKK Document 48 Filed 08/25/17 Page 1 of 5 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:17-cv-01320-CKK Document 48 Filed 08/25/17 Page 1 of 5 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ELECTRONIC PRIVACY INFORMATION CENTER, Plaintiff, v. Civil Action No. 1:17-cv-1320
More informationWe have carefully considered the Petition.! For the reasons described below, the Petition is granted.
DEPARTMENT OF HEALTH &. HUMAN SERVICES... -------------_._- Food and Drug Administration Rockville MD 20857 JUN 17 2010. Pankaj Dave, Ph.D. Vice President, Regulatory Affairs Navinta LLC 1499 Lower Ferry
More informationThe Patented Medicines (Notice of Compliance) Regulations: What patents are eligible to be listed on the register?
The Patented Medicines (Notice of Compliance) Regulations: What patents are eligible to be listed on the register? Edward Hore Hazzard & Hore 141 Adelaide Street West, Suite 1002 Toronto, ON M5H 3L5 (416)
More informationGuidance for the public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings
Reprinted from FDA s website by Guidance for the public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meetings FINAL GUIDANCE Comments and suggestions
More informationCase 1:09-cv CKK Document 5 Filed 09/24/2009 Page 1 of 10 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
Case 1:09-cv-01810-CKK Document 5 Filed 09/24/2009 Page 1 of 10 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ) WYETH PHARMACEUTICALS, ) ) Plaintiff, ) ) v. ) Civil Action No. 09-1810 ) U.S.
More informationUnited States District Court
Case:-cv-0-PJH Document Filed0// Page of UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA CENTER FOR FOOD SAFETY, et al., Plaintiffs, No. C - PJH v. ORDER MARGARET A. HAMBURG, M.D., 0 Defendant.
More informationClarification of When Products Made or Derived from Tobacco Are Regulated as Drugs,
This document is scheduled to be published in the Federal Register on 01/16/2018 and available online at https://federalregister.gov/d/2018-00555, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More information